GlaucomaNCT05954637
Correlation of Structure and Function in Glaucoma
An observational study of Glaucoma, run by Vienna Hospital Association at 1 site in Austria.
Trial summary
The aim of the study is to correlate structure and function in patients with glaucoma. To this end, a cross-sectional study unsing perimetry and optical coherence tomography is performed. Read more about this study
- Who is it for?
- Ages 18 to 100 years
- Conditions the study is for
- Glaucoma
- What is being tested?
- Optical coherence tomography
- Type of treatment
- Medical device
- How many people
- 60 participants
- Where
- 1 siteAustria
- Study dates
- 1 Jul 2023to 31 Dec 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 100 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients in the Department of Ophthalmology, Clinic Hietzing, Vienna Healthcare Group, who have been diagnosed with "glaucomatous optic neuropathy" are eligible for inclusion in the study.
Who may be able to join
- Diagnosis of glaucomatous optic neuropathy
Who cannot join
- Age < 18 years
- Diabetes
- Pregnancy
- Hypertensive retinopathy
- Smoking
- Intraocular surgery 1 month prior to study entry
Show all 9Show fewer
- Systemic or ocular disease, excluding glaucoma, which the investigator believes could affect the test results
- Insufficient quality of the optical coherence tomography imaging
- Insufficient cooperation during examinations or measurements
Trial locations and contacts
1 site in 1 country.
Austria1 site
Department of Ophthalmology, Clinic Hietzing, Vienna Healthcare Group
Vienna, State of Vienna, 1130
About this study
The aim of the study is to correlate structure and function in patients with glaucoma. To this end, a cross-sectional study unsing perimetry and optical coherence tomography is performed.
- Conditions
- Glaucoma
- Being tested
- Optical coherence tomography
- Medical subject headings
- Glaucoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Optical coherence tomographyDevice
Heidelberg Engineering Spectralis
What is being measured
The primary outcome is the main question the study is designed to answer.
Association of retinal sensitivity with peripapillary retinal nerve fiber layer thickness
Measured: 1 day
Association of retinal sensitivity with peripapillary vessel density
Measured: 1 day
Secondary outcomes (1)
Glaucoma Activity Limitation score
Measured: 1 day
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Jul 2023
- Study start1 Jul 2023
- Primary completion31 Dec 2024
- Study completion31 Dec 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for GlaucomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- Vienna Hospital Association
- Sponsor type
- Other government
- Responsible party
- Principal investigator, Prim. Univ.-Prof. Dr. Pia Veronika Vécsei-Marlovits, MSc, MB, Vienna Hospital Association
- Investigators
- Pia V Vécsei-Marlovits, MD, MSc, MBA, Principal investigator, Department of Ophthalmology, Clinic Hietzing, Vienna Healthcare Group
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05954637
- Sponsor's protocol ID
- struct_funct_glaucoma
- Status last verified
- Nov 2025
- First submitted
- 10 Jul 2023
- Last updated
- 2 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 2 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Correlation of Structure and Function in Glaucoma
- ClinicalTrials.gov ID
- NCT05954637
- Acronym / sponsor ID
- struct_funct_glaucoma
- Conditions
- Glaucoma
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 60 participants (actual)
- Lead sponsor
- Vienna Hospital AssociationOther government
- Study start
- 1 Jul 2023 (actual)
- Primary completion
- 31 Dec 2024 (actual)
- Study completion
- 31 Dec 2024 (actual)
- First posted
- 20 Jul 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of the study is to correlate structure and function in patients with glaucoma. To this end, a cross-sectional study unsing perimetry and optical coherence tomography is performed.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 18 to 100 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients in the Department of Ophthalmology, Clinic Hietzing, Vienna Healthcare Group, who have been diagnosed with "glaucomatous optic neuropathy" are eligible for inclusion in the study.
Key inclusion criteria (1 listed)
- Diagnosis of glaucomatous optic neuropathy
Key exclusion criteria (9 listed)
- Age < 18 years
- Diabetes
- Pregnancy
- Hypertensive retinopathy
- Smoking
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Optical coherence tomographyHeidelberg Engineering Spectralis | Device | – |
Primary outcome
Association of retinal sensitivity with peripapillary retinal nerve fiber layer thickness
Time frame: 1 day
Association of retinal sensitivity with peripapillary vessel density
Time frame: 1 day
1 secondary outcome
Glaucoma Activity Limitation score
Time frame: 1 day
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Dec 2025.
- Individual participant dataSharing planned: Undecided
Related trials for Glaucoma
Active, not recruitingObservational study
Impact of Glaucoma and Visual Field Loss on Life Space
Primary Open-angle Glaucoma
Active, not recruitingObservational study
Glaucoma, Visual Field Loss, and Their Association With Life Space in Older Adults
Primary Open Angle Glaucoma
Not yet recruitingPhase 2
VGFTe-(HD)-OD-2566: Adjunctive Aflibercept Ahmed Glaucoma Valve (AAA) Study
Glaucoma
Not yet recruitingPhase 4
Iopidine to Decrease Intraocular Pressure Rise After Injections
Macular Degeneration, Diabetic Retinopathy
Recruiting
Timing of Glaucoma Drainage Device With Boston Keratoprosthesis
Corneal Transplantation, Glaucoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Pia V Vécsei-Marlovits, MD, MSc, MBA principal investigator
Department of Ophthalmology, Clinic Hietzing, Vienna Healthcare Group
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Glaucoma, run by Vienna Hospital Association at 1 site in Austria.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Austria. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Association of retinal sensitivity with peripapillary retinal nerve fiber layer thickness (time frame: 1 day). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Dec 2025.